Who Owns Voltaren?

Voltaren operates within Haleon's sustainability framework, which focuses on health inclusivity, environmental responsibility, and ethical business practices. Haleon achieved all its Responsible Business goals set at its 2022 listing, including empowering 50 million people annually to access improved everyday health. The company has set a new goal of providing opportunities for over 100 million people a year to take more control of their health by 2030.

In 2025, Haleon achieved a 55% reduction in net Scope 1 and 2 carbon emissions compared to its 2020 baseline. The company achieved a 9% reduction in virgin petroleum-based plastic use. Gender representation in leadership roles reached 46.3%. Over 74 million people were empowered to be more included in opportunities for better everyday health.

Voltaren contributes to Haleon's health inclusivity mission by providing accessible over-the-counter pain relief in over 100 countries. The brand's OTC availability enables consumers to manage pain without requiring prescriptions, supporting self-care and health empowerment.

Haleon's manufacturing facilities operate under comprehensive environmental management systems. The company has implemented initiatives to reduce energy consumption, minimize waste, and decrease water usage. In 2025, Haleon's supply chain optimization reduced SKUs, packaging specifications, and formulations, contributing to both cost savings and reduced environmental impact.

Voltaren's topical delivery system provides an environmental advantage over oral medications by requiring lower doses. The brand's packaging incorporates recycled materials and design optimizations to reduce environmental footprint.

Haleon maintains ethical sourcing guidelines for raw materials, active pharmaceutical ingredients, and packaging materials. The company conducts supplier audits and requires environmental compliance, fair labor practices, and quality control throughout the supply chain.

Voltaren has received recognition for clinical efficacy, innovation in topical pain relief, and market leadership.

FDA OTC Approval (2020): Voltaren Arthritis Pain gel received FDA approval for over-the-counter sale in the United States in 2020, making it the first OTC topical NSAID approved in the US. This approval expanded consumer access to prescription-strength diclofenac gel without requiring a doctor's visit.

Market Leadership: Haleon is the global #1 in the GBP 20 billion pain relief category, with Voltaren as a key brand alongside Advil and Panadol. Voltaren maintains strong market positions in key European markets including Switzerland and Germany.

UEFA Champions League Partnership (2025): Voltaren became the official licensed pain reliever of the UEFA Champions League, a first for both Haleon and UEFA. The campaign was designed to strengthen Voltaren's relevance among younger, active consumers and culminated at the final in Munich in May 2025. The partnership was activated across broad media channels including in-store displays and experiential marketing.

Product Innovation: The launch of Voltaren patches in Europe and the 2% gel formulation in China in 2025 demonstrated the brand's continued product development. The China launch drove market share growth in the pain relief category in that market.

Clinical Validation: Voltaren has been clinically proven to provide safe and effective arthritis pain relief. Haleon's HealthPartner platform provides healthcare professionals with access to clinical study data and safety information, supporting transparency in healthcare communications.

Voltaren has maintained a strong safety record without major product recalls, but faces ongoing scrutiny regarding NSAID class safety concerns and regulatory requirements.

NSAID Class Safety Concerns: Voltaren, like all NSAID products, carries potential risks including cardiovascular events, gastrointestinal bleeding, and kidney issues. While Voltaren's topical delivery system reduces systemic absorption compared to oral NSAIDs, the brand faces ongoing scrutiny regarding class-wide safety concerns and appropriate risk communication to consumers.

FDA Regulatory Requirements: Voltaren operates under stringent FDA oversight in the United States. The FDA requires comprehensive safety labeling for NSAIDs, including warnings about cardiovascular risks, gastrointestinal bleeding, and skin application site reactions. Voltaren Arthritis Pain gel carries FDA warnings about avoiding sunlight and UV exposure on treated areas.

Cardiovascular Risk Communication: Healthcare organizations and consumer advocacy groups have raised concerns about cardiovascular risks associated with NSAID use, including topical formulations. Voltaren must balance providing effective pain relief with ensuring consumers understand potential risks, particularly for long-term use or use by individuals with pre-existing cardiovascular conditions.

Gastrointestinal Safety Profile: While Voltaren's topical application reduces gastrointestinal risks compared to oral NSAIDs, the brand still carries warnings about potential GI side effects. Consumer health advocates emphasize the importance of proper dosing and duration of use.

Prescription vs OTC Availability: In some markets, diclofenac gel remains prescription-only, creating inconsistency in Voltaren's availability across countries. In the United States, the FDA approved Voltaren for OTC use in 2020, but in other markets the regulatory status varies. This creates challenges for consumer education and consistent brand positioning globally.

Competition from Generic Diclofenac: Voltaren faces competition from generic diclofenac gel products in many markets. Once patents and exclusivity periods expire, generic manufacturers can produce and sell diclofenac gel at lower prices, potentially eroding Voltaren's market share. Haleon competes by emphasizing brand trust, formulation quality, and innovation like the patch format.

Current Status: Voltaren remains a trusted and effective topical pain relief brand within Haleon's portfolio. The brand grew low-single digit in 2025, supported by patch launches in Europe and expansion into China. Voltaren continues to invest in safety research, consumer education, and product innovation while addressing regulatory requirements through transparent communication and responsible marketing.